What it's for (Indications)
- Finasteride is indicated for the treatment of two primary conditions in adult males.
- Firstly, it is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) to reduce the size of the enlarged prostate, improve urine flow, and reduce the risk of acute urinary retention and the need for surgery related to BPH.
- The 5 mg dose is typically used for this purpose.
- Secondly, finasteride is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only, to increase hair growth and prevent further hair loss.
- The 1 mg dose is used for this indication.
- It is crucial to note that finasteride is not indicated for use in women or children for any condition.
- Its efficacy and safety have been established only within these specified male populations and indications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of finasteride varies depending on the medical condition being treated. For the management of benign prostatic hyperplasia (BPH), the prescribed dosage is typically 5 mg administered orally once daily. Consistent daily administration is critical, and therapeutic effects may take several months to become evident, often requiring a minimum of six months of treatment to assess efficacy. For the treatment of male pattern hair loss (androgenetic alopecia), the recommended dosage is 1 mg administered orally once daily. Similarly, sustained daily use is necessary, and at least three months of treatment are generally required before hair growth improvement or prevention of further loss can be observed. Discontinuation of treatment for either indication typically leads to reversal of the beneficial effects within 6 to 12 months. Patients should be advised to take the tablet with or without food, and to swallow it whole, without crushing or breaking. |
Safety & Warnings
Common Side Effects
- Finasteride is generally well-tolerated, but a range of side effects has been reported.
- Common adverse reactions, particularly associated with the 5 mg dose for BPH, include sexual dysfunction such as decreased libido (reduced sex drive), erectile dysfunction (difficulty achieving or maintaining an erection), and ejaculation disorder (e.
- g.
- , decreased ejaculate volume).
- These sexual side effects have also been reported with the 1 mg dose for hair loss, though generally at lower incidences.
- Other reported side effects include breast tenderness and enlargement (gynecomastia), testicular pain, and skin rash.
- More serious, albeit rare, side effects can include allergic reactions (e.
- g.
- , swelling of the lips, face, tongue, and throat; hives), depression, and, in some cases, suicidal ideation.
- There have also been reports of male breast cancer and high-grade prostate cancer associated with finasteride use, requiring careful monitoring and patient education.
- Some sexual adverse reactions, including decreased libido, erectile dysfunction, and ejaculation disorder, have been reported to persist after discontinuation of treatment, a phenomenon sometimes referred to as Post-Finasteride Syndrome.
- Patients should be counseled on all potential adverse effects.
Serious Warnings
- Black Box Warning: Finasteride does not carry a formal Black Box Warning from the U.S. Food and Drug Administration (FDA). However, several critical safety concerns warrant detailed attention, similar to the gravity implied by a boxed warning. A paramount concern is the **teratogenic potential** of finasteride. It is strictly contraindicated in women who are or may become pregnant due to the risk of causing external genital abnormalities in a male fetus. Pregnant women should not handle crushed or broken tablets. Another significant concern involves its effect on **prostate-specific antigen (PSA) levels**, which are reduced by approximately 50%. This can mask the detection of prostate cancer, requiring careful adjustment and interpretation of PSA values in men taking finasteride. Furthermore, studies have indicated an increased risk of **high-grade prostate cancer** in men treated with the 5 mg dose. Clinicians must conduct thorough prostate cancer screenings before and during treatment. Reports of **male breast cancer** have been noted, and patients should be advised to report any breast changes promptly. Lastly, there are documented instances of **persistent sexual adverse reactions**, including decreased libido, erectile dysfunction, and ejaculation disorders, which may continue even after discontinuation of the drug. Additionally, mood changes, including **depression and suicidal ideation**, have been reported, necessitating monitoring for psychiatric symptoms. These serious safety considerations underscore the importance of comprehensive patient counseling and diligent medical oversight.
- Patients receiving finasteride require careful monitoring due to several significant warnings.
- Finasteride can cause a decrease in serum prostate-specific antigen (PSA) levels by approximately 50% in men with BPH, even in the presence of prostate cancer.
- This reduction must be accounted for when interpreting PSA results, as it can mask the presence of prostate cancer, leading to delayed diagnosis.
- Before initiating finasteride, and periodically thereafter, clinicians should perform digital rectal examinations and other evaluations for prostate cancer.
- In clinical trials, the 5 mg dose of finasteride was associated with an increased risk of developing high-grade prostate cancer.
- Furthermore, finasteride is contraindicated in women who are or may become pregnant due to its potential to cause abnormalities of the external genitalia in a male fetus.
- Pregnant women should not handle crushed or broken finasteride tablets.
- Sexual adverse reactions, including decreased libido, erectile dysfunction, and ejaculation disorders, have been reported to persist even after discontinuing finasteride.
- Patients should be informed about the potential for these persistent sexual side effects.
- Cases of male breast cancer have been reported, and patients should be advised to promptly report any breast lumps, pain, nipple discharge, or other breast changes.
- Additionally, mood alterations, including depression and, rarely, suicidal ideation, have been reported; patients should be monitored for psychiatric symptoms.
How it Works (Mechanism of Action)
Finasteride exerts its therapeutic effects by specifically inhibiting the enzyme 5-alpha-reductase. This enzyme exists in two main isoenzymatic forms: Type 1 and Type 2. Finasteride is a potent and highly selective inhibitor primarily of the Type 2 isoenzyme of human 5-alpha-reductase, and to a lesser extent, the Type 3 isoenzyme. The Type 2 isoenzyme is predominantly found in the prostate gland, seminal vesicles, epididymides, and hair follicles, as well as the liver and skin. By inhibiting 5-alpha-reductase, finasteride prevents the conversion of testosterone into dihydrotestosterone (DHT). DHT is a potent androgen responsible for the growth and development of the prostate gland. In benign prostatic hyperplasia, elevated levels of DHT within the prostate contribute to prostate enlargement. By reducing systemic and intraprostatic DHT levels, finasteride causes regression of the enlarged prostate tissue, leading to improved urinary flow and a reduction in BPH-related symptoms. Similarly, in androgenetic alopecia, DHT is a key factor in the miniaturization of hair follicles on the scalp, leading to hair loss. By lowering scalp DHT levels, finasteride helps to reverse the hair loss process and promote hair regrowth. This targeted enzymatic inhibition underlies its efficacy in both indications.